ATORVASTATIN-EXCIPIENT COMPATIBILITY STUDIES TO DEVELOPMENT CREAM NOVEL DRUG DELIVERY SYSTEMS FOR ENHANCED DIABETIC WOUND HEALING

Chronic diabetic wounds are challenging to treat due to combined issues of impaired tissue repair and high infection risk. Atorvastatin (a statin with pleiotropic effects) and Fusidic acid (an antibiotic effective against skin pathogens including MRSA) each address different facets of diabetic wound pathology. The main objective of the present study was to the preformulation studies were performed to know the development of formulation and evaluation of Atorvastatin Cream NDDS for topical application. In the present study that the compatibility was assessed by, FTIR spectroscopy, and melting point apparatus, preformulation parameters. Results showed that physical mixtures of Atorvastatin and various excipients such as cetostearyl alcohol, stearic acid, Vaseline (petroleum jelly), liquid paraffin, antioxidant: butylated hydroxyanisole (BHA), preservative: chlorocresol, aqueous phase components: propylene glycol, and emulsifier: Tween 80 were evaluated for preformulation studies parameters were investigated by FTIR it was detected that there was no variation or minor deviation in the characteristic peaks in FTIR spectroscopy. It was concluded that the drug Atorvastatin was found to be compatible with various excipients which were selected for the formulation development of the Atorvastatin Cream NDDS. These formulations favorable properties and efficacy indicate it as a promising strategy for improving outcomes in infected diabetic wounds. Formulation scientist from his experience and knowledge have to significantly in the preformulation study stage and is an important factor in the ADDS (Advanced Drug Delivery Systems) product development process.